KNSA Stock Analysis: Buy, Sell, or Hold?
KNSA - Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
$56.51
-2.03 (-3.47%)
▼
5d:
-3.57%
30d:
+24.69%
90d:
+24.55%
BUY
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 05, 2026
0d
Get Alerted When KNSA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KNSA shows positive signals but monitor for confirmation. Market pricing in 6.4% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: KNSA shows positive signals but monitor for confirmation. Market pricing in 6.4% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$85.56
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$53.13
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KNSA is currently trading at $56.51, which is considered slightly high relative to its 30-day fair value range of $44.71 to $56.87. From a valuation perspective, the stock is trading at a premium (Forward PE: 32.1) compared to its historical average (26.7). At these levels, the market is pricing in 6.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, KNSA is in a strong uptrend. Immediate support is located at $54.45, while resistance sits at $59.87. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: KNSA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $63.50 (+12.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KNSA is in a strong uptrend. Immediate support is located at $54.45, while resistance sits at $59.87. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: KNSA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $63.50 (+12.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$44.71 -
$56.87
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
69.0%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading below Wall St target ($63.50)
- NEUTRAL: PE elevated vs history but 6.4% growth expectation is conservative given 146% recent growth
Trading Range Analysis
30-Day Trading Range
$44.71 -
$56.87
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$54.45
Resistance Level
$59.87
Current Trend
Strong Uptrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
32.15
Wall Street Target
$63.50
(+12.4%)
Revenue Growth (YoY)
55.5%
Earnings Growth (YoY)
145.5%
Profit Margin
9.7%
Valuation Premium vs History
+6.4% premium
PE vs Historical
32.2 vs 26.7
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.4%
(market-implied from PE analysis)
1-Year Target
$60.13
(+6%)
2-Year Target
$63.97
(+13%)
3-Year Target
$68.07
(+21%)
3-Yr Target (if PE normalizes)
(PE: 32→27)
PE COMPRESSION
$56.52
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 32.2, Growth: 46.5%)
$177.53
(+214%)
Base:
(SPY PE: 22.1, Growth: 46.5%)
$121.85
(+116%)
Bear:
(PE: 18.8, Growth: 46.5%)
$103.58
(+83%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (64x PE), but valuation improves significantly next year (32x PE) as earnings recover.
Trailing PE: 64.33 | Current EPS (TTM): $0.91
Bull Case
$124.37
(+120%)
Analyst growth 93.1%, PE expands to 70.8
Base Case
$113.06
(+100%)
Market implied 93.1%, PE stable at 64.3
Bear Case
$39.81
(-30%)
Severe decline -20.0%, PE contracts to 54.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: May 15, 2026 9:10 PM ET
Data refreshes hourly during market hours. Next update: 10:10 PM
Data refreshes hourly during market hours. Next update: 10:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KNSA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
17
Sells
Net
INSIDERS SELLING
Recent Transactions
Ross Moat
SELL
1703 shares
2026-04-09
Michael R Megna
SELL
6625 shares
2026-04-09
Barry D Quart
SELL
6901 shares
2026-04-06
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$136 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$102 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 58 HOLD |
Advanced KNSA Option Strategies
Professional options setups generated by AI based on today's KNSA price and gamma walls.
